Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International (OTC BB:GCAN) today announced
that Patrick Schnegelsberg, CEO, participated at and presented at the
2006 Vitiligo Support National Conference held at the Hilton Universal
City near Los Angeles in California from July 14th through the 16th.
The conference featured individuals with vitiligo, physicians and
other experts in vitiligo treatments, pathology, new research,
autoimmune diseases and more.
"GammaCan is aiming at becoming actively involved and work with
the vitiligo community. In addition, we are exploring if we could be
in a position to provide needed options to the vitiligo community
while at the same time assisting patients suffering from metastatic
malignant melanoma. VitiGam, an innovative anti-cancer product
designed to treat Stage III and IV melanoma, may play a role here,"
stated Patrick Schnegelsberg.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam enter phase I/II testing under a US IND in the near
future after recently holding a pre-IND meeting with the FDA. VitiGam
is being designed to target metastatic melanoma patients with Stage
III and IV melanoma. VitiGam is an IgG product that is different from
standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.
About Vitiligo Support International:
Vitiligo Support International, the largest vitiligo organization
in the world, is a global community organization committed to
supporting those affected by vitiligo, raising awareness, promoting
research, and discussing effective treatments until a cure is found.
Their website is at www.VitiligoSupport.org
About GammaCan:
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IVIg, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IVIg works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IVIg
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IVIg and vitiligo-derived IVIg
(VitiGam).
For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIg into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.